“APAC, post-COVID-19, will see an explosion of innovation in digital health”
BioSpectrum Asia|August 2020
The ongoing COVID-19 pandemic plaguing countries worldwide has created unprecedented change for the global economy, especially healthcare institutions at the forefront. Hospitals across the world are facing never before seen challenges that have accelerated the development of technological innovations. As we navigate the complexities of the virus and the amount of disruption it has brought about, one thing is certain – COVID-19 will be with us for the foreseeable future. It’s time to focus on this new reality and how we can achieve a sense of normalcy. Dr. Ian Chuang, who is currently the Chief Medical Officer at Elsevier shares his insights on how the healthcare ecosystem can prepare for the ‘new normal’ in a post-COVID-19 world. Edited excerpts;
Hithaishi C Bhaskar
“APAC, post-COVID-19, will see an explosion of innovation in digital health”

Dr Ian Chuang, Chief Medical Officer, EMEALAAP Health, Elsevier, Kansas City, Missouri Area, USA

How can healthcare ecosystems establish a strategic and resilient pandemic preparedness model?

There are and continue to be many lessons to be learned from this pandemic. Some of the areas are broad and systemic, requiring larger-scale evaluation of the fundamentals of the healthcare system and model of care itself. Ideally, we proceed with any change in a human-centered design thinking approach.

With many uncertainties about the disease, the COVID-19 pandemic has highlighted the importance of accessible and trusted data for frontline clinicians providing care. The pandemic crisis has sped up the delivery and accentuated the weakness in the healthcare system. The healthcare system was not ready when the disease first broke, putting a strain on the entire health system. As healthcare workers were over-taxed and reacting to the evolving crisis, patients were left to figure things out on their own. There was no recipe to fall back. Doctors’ offices were closed, elective surgeries canceled, and patients did not know where to seek care, let alone whether the Emergency Department was safe. The healthcare system was barely keeping up with the demands of COVID-19 related care; definitely, there was a shortfall of how well other care needs were met.

Esta historia es de la edición August 2020 de BioSpectrum Asia.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.

Esta historia es de la edición August 2020 de BioSpectrum Asia.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.

MÁS HISTORIAS DE BIOSPECTRUM ASIAVer todo
Ushering Fourth Industrial Revolution in Telangana
BioSpectrum Asia

Ushering Fourth Industrial Revolution in Telangana

Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).

time-read
6 minutos  |
BioSpectrum Asia April 2024
How Indian Biotech Investments are on a Doubling Spree
BioSpectrum Asia

How Indian Biotech Investments are on a Doubling Spree

A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.

time-read
4 minutos  |
BioSpectrum Asia April 2024
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
BioSpectrum Asia

"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”

South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.

time-read
5 minutos  |
BioSpectrum Asia April 2024
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
BioSpectrum Asia

"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"

Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.

time-read
4 minutos  |
BioSpectrum Asia April 2024
Can Test, Treat, Track Beat Malaria?
BioSpectrum Asia

Can Test, Treat, Track Beat Malaria?

Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.

time-read
8 minutos  |
BioSpectrum Asia April 2024
Engineering CAR T cell sharpshooters
BioSpectrum Asia

Engineering CAR T cell sharpshooters

Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.

time-read
6 minutos  |
BioSpectrum Asia April 2024
Addressing Challenges in Cell Therapy Manufacturing
BioSpectrum Asia

Addressing Challenges in Cell Therapy Manufacturing

Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.

time-read
2 minutos  |
BioSpectrum Asia April 2024
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
BioSpectrum Asia

"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"

Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.

time-read
5 minutos  |
BioSpectrum Asia April 2024
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
BioSpectrum Asia

Addressing Accessibility and Affordability of CELL & GENE THERAPIES

Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.

time-read
10+ minutos  |
BioSpectrum Asia April 2024
Korea designs sweat resistant wearable robot sensor
BioSpectrum Asia

Korea designs sweat resistant wearable robot sensor

New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.

time-read
1 min  |
March 2024